MXPA03002269A - Derivados de purina. - Google Patents

Derivados de purina.

Info

Publication number: MXPA03002269A
Authority: MX; Mexico
Prior art keywords: purine derivatives; purine; derivatives
Prior art date: 2000-09-15

Application number

MXPA03002269A

Other languages

English (en)

Inventor

Simon John Mantell

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-15

Filing date

2001-09-03

Publication date

2003-06-06

2001-09-03 Application filed by Pfizer filed Critical Pfizer

2003-06-06 Publication of MXPA03002269A publication Critical patent/MXPA03002269A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)

MXPA03002269A 2000-09-15 2001-09-03 Derivados de purina. MXPA03002269A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0022695.1A GB0022695D0 (en)	2000-09-15	2000-09-15	Purine Derivatives
PCT/IB2001/001612 WO2002022630A1 (en)	2000-09-15	2001-09-03	Purine derivatives

Publications (1)

Publication Number	Publication Date
MXPA03002269A true MXPA03002269A (es)	2003-06-06

Family

ID=9899551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03002269A MXPA03002269A (es)	2000-09-15	2001-09-03	Derivados de purina.

Country Status (17)

Country	Link
US (1)	US6624158B2 (es)
EP (1)	EP1317465A1 (es)
JP (1)	JP2004509130A (es)
AP (1)	AP2001002287A0 (es)
AU (1)	AU2001284333A1 (es)
BR (1)	BR0114089A (es)
CA (1)	CA2422374C (es)
DO (1)	DOP2001000247A (es)
GB (1)	GB0022695D0 (es)
GT (1)	GT200100187A (es)
MX (1)	MXPA03002269A (es)
PA (1)	PA8528501A1 (es)
PE (1)	PE20011269A1 (es)
SV (1)	SV2002000630A (es)
TN (1)	TNSN01134A1 (es)
UY (1)	UY26933A1 (es)
WO (1)	WO2002022630A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) *	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
US6232297B1 (en) *	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
AU2002362443B2 (en) *	2001-10-01	2008-05-15	University Of Virginia Patent Foundation	2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
JP2006515829A (ja) *	2002-04-10	2006-06-08	ユニバーシティオブバージニアパテントファウンデーション	炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
AU2002951247A0 (en)	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
WO2006028618A1 (en) *	2004-08-02	2006-03-16	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1778712B1 (en) *	2004-08-02	2013-01-30	University Of Virginia Patent Foundation	2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) *	2004-08-02	2006-03-02	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having a2a agonist activity
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0500785D0 (en) *	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
KR100801550B1 (ko)	2005-09-30	2008-02-11	대한민국	누에 수번데기로부터 아데노신 유도체 화합물을 정제하는방법 및 아데노신 유도체 화합물을 포함하는 발기부전치료용 조성물
EP2532678A1 (en)	2005-10-21	2012-12-12	Novartis AG	Human antibodies against il13 and therapeutic uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
US20080027022A1 (en) *	2006-02-08	2008-01-31	Linden Joel M	Method to treat gastric lesions
US8178509B2 (en)	2006-02-10	2012-05-15	University Of Virginia Patent Foundation	Method to treat sickle cell disease
EP2021350B1 (en)	2006-03-21	2016-12-21	Rheinische Friedrich-Wilhelms-Universität Bonn	Phosphorylated a2a receptor agonists
GB0607954D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
US8188063B2 (en) *	2006-06-19	2012-05-29	University Of Virginia Patent Foundation	Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (en) *	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
EP1903044A1 (en)	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
JP2010504933A (ja)	2006-09-29	2010-02-18	ノバルティスアーゲー	Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt)	2006-10-30	2014-01-07	Novartis Ag	Compostos heterocíclicos como agentes anti-inflamatórios.
US8058259B2 (en) *	2007-12-20	2011-11-15	University Of Virginia Patent Foundation	Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
PT2231642E (pt)	2008-01-11	2014-03-12	Novartis Ag	Pirimidinas como inibidores de quinase
WO2010088335A1 (en)	2009-01-29	2010-08-05	Novartis Ag	Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko)	2009-08-12	2012-08-13	노파르티스 아게	헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
PE20170003A1 (es)	2009-08-17	2017-03-15	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
IN2012DN01453A (es)	2009-08-20	2015-06-05	Novartis Ag
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
US8637516B2 (en)	2010-09-09	2014-01-28	Irm Llc	Compounds and compositions as TRK inhibitors
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
EA201391230A1 (ru)	2011-02-25	2014-01-30	АйАрЭм ЭлЭлСи	Соединения и композиции в качестве ингибиторов trk
UY34329A (es)	2011-09-15	2013-04-30	Novartis Ag	Compuestos de triazolopiridina
WO2013078440A2 (en)	2011-11-23	2013-05-30	Intellikine, Llc	Enhanced treatment regimens using mtor inhibitors
WO2013149581A1 (en)	2012-04-03	2013-10-10	Novartis Ag	Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
EP3174869B1 (en)	2014-07-31	2020-08-19	Novartis AG	Combination therapy of a met inhibitor and an egfr inhibitor
CA3102279A1 (en)	2018-06-01	2019-12-05	Cornell University	Combination therapy for pi3k-associated disease or disorder
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU8276187A (en)	1986-10-31	1988-05-25	Warner-Lambert Company	Selected n6-substituted adenosines having selective a2 binding activity
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IL107101A0 (en)	1992-09-30	1993-12-28	Merrell Dow Pharma	2-substituted adenosines with a-2 receptor affinity
WO1998001459A1 (en)	1996-07-05	1998-01-15	Novo Nordisk A/S	Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
TW528755B (en)	1996-12-24	2003-04-21	Glaxo Group Ltd	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB9723590D0 (en)	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
AU2108299A (en)	1998-01-08	1999-07-26	University Of Virginia Patent Foundation	A2A adenosine receptor agonists
YU44900A (sh)	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es)	1998-02-14	2000-12-26	Glaxo Group Ltd	Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
GB9813565D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813535D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
AU750462B2 (en)	1998-06-23	2002-07-18	Glaxo Group Limited	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
ATE331726T1 (de)	1998-10-16	2006-07-15	Pfizer	Adenine-derivate
GB9913932D0 (en)	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
GB9924363D0 (en)	1999-10-14	1999-12-15	Pfizer Central Res	Purine derivatives
GB9924361D0 (en)	1999-10-14	1999-12-15	Pfizer Ltd	Purine derivatives
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives

2000
- 2000-09-15 GB GBGB0022695.1A patent/GB0022695D0/en not_active Ceased
2001
- 2001-08-20 US US09/933,421 patent/US6624158B2/en not_active Expired - Fee Related
- 2001-09-03 AP APAP/P/2001/002287A patent/AP2001002287A0/en unknown
- 2001-09-03 CA CA002422374A patent/CA2422374C/en not_active Expired - Fee Related
- 2001-09-03 EP EP01963310A patent/EP1317465A1/en not_active Withdrawn
- 2001-09-03 JP JP2002526881A patent/JP2004509130A/ja not_active Ceased
- 2001-09-03 BR BR0114089-2A patent/BR0114089A/pt not_active IP Right Cessation
- 2001-09-03 MX MXPA03002269A patent/MXPA03002269A/es active IP Right Grant
- 2001-09-03 WO PCT/IB2001/001612 patent/WO2002022630A1/en not_active Ceased
- 2001-09-03 AU AU2001284333A patent/AU2001284333A1/en not_active Abandoned
- 2001-09-05 PA PA20018528501A patent/PA8528501A1/es unknown
- 2001-09-10 GT GT200100187A patent/GT200100187A/es unknown
- 2001-09-12 UY UY26933A patent/UY26933A1/es not_active Application Discontinuation
- 2001-09-13 PE PE2001000922A patent/PE20011269A1/es not_active Application Discontinuation
- 2001-09-14 TN TNTNSN01134A patent/TNSN01134A1/fr unknown
- 2001-09-14 SV SV2001000630A patent/SV2002000630A/es unknown
- 2001-09-14 DO DO2001000247A patent/DOP2001000247A/es unknown

Also Published As

Publication number	Publication date
SV2002000630A (es)	2002-12-02
AP2001002287A0 (en)	2001-12-31
UY26933A1 (es)	2002-04-26
WO2002022630A1 (en)	2002-03-21
BR0114089A (pt)	2003-07-01
AU2001284333A1 (en)	2002-03-26
CA2422374C (en)	2007-02-20
EP1317465A1 (en)	2003-06-11
JP2004509130A (ja)	2004-03-25
GB0022695D0 (en)	2000-11-01
PE20011269A1 (es)	2001-12-18
US20020072597A1 (en)	2002-06-13
US6624158B2 (en)	2003-09-23
PA8528501A1 (es)	2002-07-30
GT200100187A (es)	2002-04-22
CA2422374A1 (en)	2002-03-21
TNSN01134A1 (fr)	2005-11-10
DOP2001000247A (es)	2002-05-30

Publication	Publication Date	Title
MXPA03002269A (es)	2003-06-06	Derivados de purina.
MXPA03000078A (es)	2003-08-19	Derivados de purina.
GC0000287A (en)	2006-11-01	Purine derivatives
MXPA03001775A (es)	2003-06-04	Derivados de nucleosidos.
MXPA02003750A (es)	2003-10-14	Derivados de purina.
ZA200202849B (en)	2003-06-25	Purine derivatives.
ZA200110208B (en)	2002-12-12	Purine derivatives.
IL150543A0 (en)	2003-02-12	Purine derivatives
ZA200207331B (en)	2003-09-12	Ethylenediamine derivatives.
HRP20030055A2 (en)	2005-02-28	4-phenyl-pyridine derivatives
IL150841A0 (en)	2003-02-12	1h-imidazopyridine derivatives
EG23262A (en)	2004-10-31	Delta -pyrrolines.
MXPA03004857A (es)	2003-08-19	Derivados de purina condensados como antagonistas del receptor de adenosina a1.
MXPA03001591A (es)	2003-09-10	Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es)	2003-06-24	2-guanidin-4-arilquinazolinas.
ZA200205482B (en)	2003-12-31	Aminosulfonylbiphenyl derivatives.
MXPA03004453A (es)	2003-08-19	Derivados de pirimidina.
ZA200206151B (en)	2003-11-03	Substituted amionomethyl-phenyl-cyclohexane derivatives.
MXPA03002737A (es)	2004-01-26	Derivados sustituidos de 1-aminobutan-3-ol.
ZA200206150B (en)	2003-11-03	Aminomethyl-phenyl-cyclohexanone derivatives.
MXPA03000504A (es)	2003-06-24	Derivados de pirimidina.
MXPA03002734A (es)	2003-07-28	Derivados de 5-amino-1-penten-3-ol sustituidos.
IL151598A0 (en)	2003-04-10	2-phenylpyran-4-one derivatives
GB0018246D0 (en)	2000-09-13	Purine derivatives
GB0024920D0 (en)	2000-11-22	Purine derivatives

Legal Events

Date	Code	Title	Description
2006-05-04	FG	Grant or registration